Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma

NCT00142571 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Sarcoma, Soft Tissue

Interventions

DRUG: Gemcitabine
DRUG: Docetaxel

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]